Article in Time Magazine - Chronic Pain

[Guest guest]

In this article, here’s a couple of extracts (someone needs to tell them about LDN)! Most studies of chronic pain involve people with fibromyalgia, a condition involving abnormal pain responses that generally affects women. Chronic fatigue syndrome and back disorders can also cause constant pain, and studies of patients with all these conditions have found these individuals have more-active nerve responses, which amplify pain receptors throughout the body. This can set off the pain cascade with hair-trigger sensitivity. (See a special report on women and health.)Fibromyalgia patients are a case in point. They often report deep aches as well as shooting discomfort from their joints, even if they don't show signs of inflammation there. What they frequently do have, however, are lower levels of endorphins compared with those who don't suffer from the condition. This may make them more sensitive to pain. Endorphins are the body's natural morphine, and they dull pain by binding to nerve-cell receptors reserved for opiates. Also linked to mood, endorphins can contribute to feelings of euphoria and satisfaction, another mechanism by which they may divert the brain from pain.The body's natural painkilling system — the opioids and analgesics we all produce — are the basis for our most powerful painkillers, including nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen. All of them, natural and synthetic, work by stopping pain signals from speeding along neural highways into the spinal cord and brain. But there may be a more direct way to exploit this pain-dampening system than with drugs that diffuse throughout the entire body. That's what Dr. Fink, director of neurology at the University of Michigan, is hoping to show with a gene-therapy study, in which he will inject chronic-pain sufferers with genes coding for natural painkillers, hoping to boost their bodies' levels of those analgesic chemicals. Enkephalins are a type of opiate that the body produces to dull pain sensations, but in cases of chronic pain, these agents appear not to flow in sufficient quantities. So in the first study of its kind, Fink's team is testing whether using a viral vector to inject cancer patients with the gene associated with enkephalins can boost levels of the opiate and address the subjects' pain. " If we could deliver the gene that makes enkephalins, " he says, " they could be released from cells directly into the nervous system and potentially reduce pain in a more targeted fashion. " Read more: http://www.time.com/time/specials/packages/article/0,28804,2053382_2053379_2053375,00.html #ixzz1FZZVOFgT Definitely a case for taking LDN! Somebody needs to tell them about how LDN works!! Jayne Crocker www.LDNNow.comImportant! Please sign our LDN petition to the European Parliament by clicking heretel: +44 (0) 7877 492 669Dr Steele MBE, talking about LDNLDNNow are a political/pressure group of individuals dedicated to getting Low Dose Naltrexone (LDN) accepted into modern medicine and trialled for the myriad of uses it shows benefit for. .

[Guest guest]

For everyone’s info, I just sent Dr Fink an email re the below:- Dear Dr Fink, Regarding the above article that appeared in The Times, I am writing to you in the hopes you will take an interest in Low Dose Naltrexone (LDN) specifically related to the paragraph highlighted below:-That's what Dr. Fink, director of neurology at the University of Michigan, is hoping to show with a gene-therapy study, in which he will inject chronic-pain sufferers with genes coding for natural painkillers, hoping to boost their bodies' levels of those analgesic chemicals. Enkephalins are a type of opiate that the body produces to dull pain sensations, but in cases of chronic pain, these agents appear not to flow in sufficient quantities. So in the first study of its kind, Fink's team is testing whether using a viral vector to inject cancer patients with the gene associated with enkephalins can boost levels of the opiate and address the subjects' pain. " If we could deliver the gene that makes enkephalins, " he says, " they could be released from cells directly into the nervous system and potentially reduce pain in a more targeted fashion. " LDN (Low Dose Naltrexone) is a decoy for blocking opioids and opioid receptors - this causes an elevation in opioids and receptors. In the interval after LDN leaves - usually 4-6 hours but dependent on many factors - the high levels of opioids interact with the high level of receptors and you get a very big response. This response comes in a variety of ways - we have discovered that cell proliferation and pain are minimized. Hence, cancer or autoimmune diseases are attenuated. LDN produces OGF (Opioid Growth Factor – met enkephalin) and I strongly encourage you to look into Dr Zagon’s work who is the founder/researcher of LDN/OGF. I am attaching a link to a list of papers that have been published http://fred.psu.edu/ds/retrieve/fred/investigator/isz1/completepub I hope I can encourage you to take the time to look at this site www.ldnscience.org which explains LDN and OGF. You will find all trials/studies there. Dr Zagon can be contacted at isz1@... Jayne Crocker www.LDNNow.comImportant! Please sign our LDN petition to the European Parliament by clicking heretel: +44 (0) 7877 492 669Dr Steele MBE, talking about LDNLDNNow are a political/pressure group of individuals dedicated to getting Low Dose Naltrexone (LDN) accepted into modern medicine and trialled for the myriad of uses it shows benefit for. . From: jaynelcrocker [mailto:jaynelcrocker@...] Sent: 03 March 2011 21:15'low dose naltrexone 'Subject: Article in Time Magazine - Chronic Pain In this article, here’s a couple of extracts (someone needs to tell them about LDN)! Most studies of chronic pain involve people with fibromyalgia, a condition involving abnormal pain responses that generally affects women. Chronic fatigue syndrome and back disorders can also cause constant pain, and studies of patients with all these conditions have found these individuals have more-active nerve responses, which amplify pain receptors throughout the body. This can set off the pain cascade with hair-trigger sensitivity. (See a special report on women and health.)Fibromyalgia patients are a case in point. They often report deep aches as well as shooting discomfort from their joints, even if they don't show signs of inflammation there. What they frequently do have, however, are lower levels of endorphins compared with those who don't suffer from the condition. This may make them more sensitive to pain. Endorphins are the body's natural morphine, and they dull pain by binding to nerve-cell receptors reserved for opiates. Also linked to mood, endorphins can contribute to feelings of euphoria and satisfaction, another mechanism by which they may divert the brain from pain.The body's natural painkilling system — the opioids and analgesics we all produce — are the basis for our most powerful painkillers, including nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen. All of them, natural and synthetic, work by stopping pain signals from speeding along neural highways into the spinal cord and brain. But there may be a more direct way to exploit this pain-dampening system than with drugs that diffuse throughout the entire body. That's what Dr. Fink, director of neurology at the University of Michigan, is hoping to show with a gene-therapy study, in which he will inject chronic-pain sufferers with genes coding for natural painkillers, hoping to boost their bodies' levels of those analgesic chemicals. Enkephalins are a type of opiate that the body produces to dull pain sensations, but in cases of chronic pain, these agents appear not to flow in sufficient quantities. So in the first study of its kind, Fink's team is testing whether using a viral vector to inject cancer patients with the gene associated with enkephalins can boost levels of the opiate and address the subjects' pain. " If we could deliver the gene that makes enkephalins, " he says, " they could be released from cells directly into the nervous system and potentially reduce pain in a more targeted fashion. " Read more: http://www.time.com/time/specials/packages/article/0,28804,2053382_2053379_2053375,00.html #ixzz1FZZVOFgT Definitely a case for taking LDN! Somebody needs to tell them about how LDN works!! Jayne Crocker www.LDNNow.comImportant! Please sign our LDN petition to the European Parliament by clicking heretel: +44 (0) 7877 492 669Dr Steele MBE, talking about LDNLDNNow are a political/pressure group of individuals dedicated to getting Low Dose Naltrexone (LDN) accepted into modern medicine and trialled for the myriad of uses it shows benefit for. .

[Guest guest]

>

> For everyone's info, I just sent Dr Fink an email re the below:-

> Dear Dr Fink,

> Regarding the above article that appeared in The Times, I am writing to you

> in the hopes you will take an interest in Low Dose Naltrexone (LDN)

>.......

(someone needs to tell them about LDN)!

________________________________________

Good one Jayne!

Whenever I say to myself, " Someone needs to do something... " , my next thought is

that maybe that someone should be me!

K.C.